Discovery of triarylethanolamine inhibitors of the Kv1.5 potassium channel.

[1]  J. Tamargo,et al.  IKur/Kv1.5 channel blockers for the treatment of atrial fibrillation , 2009 .

[2]  M. Bilodeau,et al.  Kv1.5 blockers for the treatment of atrial fibrillation: approaches to optimization of potency and selectivity and translation to in vivo pharmacology. , 2009, Current topics in medicinal chemistry.

[3]  B. McBride.  The Emerging Role of Antiarrhythmic Compounds With Atrial Selectivity in the Management of Atrial Fibrillation , 2009, Journal of clinical pharmacology.

[4]  D. Darbar,et al.  Clinical use of and future perspectives on antiarrhythmic drugs , 2008, European Journal of Clinical Pharmacology.

[5]  N. Liverton,et al.  Atrial Antifibrillatory Effects of Structurally Distinct IKur Blockers 3-[(Dimethylamino)methyl]-6-methoxy-2-methyl-4-phenylisoquinolin-1(2H)-one and 2-Phenyl-1,1-dipyridin-3-yl-2-pyrrolidin-1-yl-ethanol in Dogs with Underlying Heart Failure , 2008, Journal of Pharmacology and Experimental Therapeutics.

[6]  Q. You,et al.  Strategies for atrial fibrillation therapy: focusing on IKur potassium channel , 2007 .

[7]  C. Bever,et al.  Potassium channel blockers and openers as CNS neurologic therapeutic agents. , 2007, Recent patents on CNS drug discovery.

[8]  K. K. Nanda,et al.  Potent antagonists of the Kv1.5 potassium channel: synthesis and evaluation of analogous N,N-diisopropyl-2-(pyridine-3-yl)acetamides. , 2006, Bioorganic & medicinal chemistry letters.

[9]  Kenneth D Anderson,et al.  Design and synthesis of novel isoquinoline-3-nitriles as orally bioavailable Kv1.5 antagonists for the treatment of atrial fibrillation. , 2006, Journal of medicinal chemistry.

[10]  B. Fermini,et al.  Novel, Potent Inhibitors of Human Kv1.5 K+ Channels and Ultrarapidly Activating Delayed Rectifier Potassium Current , 2006, Journal of Pharmacology and Experimental Therapeutics.

[11]  A. Waldo.  A perspective on antiarrhythmic drug therapy to treat atrial fibrillation: there remains an unmet need. , 2006, American heart journal.

[12]  N. Liverton,et al.  Synthesis of the first sulfur-35-labeled hERG radioligand. , 2006, Bioorganic & medicinal chemistry letters.

[13]  C. Regan,et al.  In Vivo Cardiac Electrophysiologic Effects of a Novel Diphenylphosphine Oxide IKur Blocker, (2-Isopropyl-5-methylcyclohexyl) Diphenylphosphine Oxide, in Rat and Nonhuman Primate , 2006, Journal of Pharmacology and Experimental Therapeutics.

[14]  J. Deuchars,et al.  Immunohistochemical localisation of the voltage gated potassium ion channel subunit Kv3.3 in the rat medulla oblongata and thoracic spinal cord , 2006, Brain Research.

[15]  G. Mensah,et al.  Atrial fibrillation: public health implications. , 2005, American journal of preventive medicine.

[16]  B. Stambler,et al.  New antiarrhythmic drugs for prevention of atrial fibrillation. , 2005, Progress in cardiovascular diseases.

[17]  Rena Zhang,et al.  Novel Method to Assess Cardiac Electrophysiology in the Rat: Characterization of Standard Ion Channel Blockers , 2005, Journal of cardiovascular pharmacology.

[18]  Wei Zheng,et al.  High throughput assay technologies for ion channel drug discovery. , 2004, Assay and drug development technologies.

[19]  J. Devaux,et al.  Effects of K+ channel blockers on developing rat myelinated CNS axons: identification of four types of K+ channels. , 2002, Journal of neurophysiology.

[20]  B. Gersh,et al.  Epidemiology and natural history of atrial fibrillation: clinical implications. , 2001, Journal of the American College of Cardiology.

[21]  S. Nattel,et al.  Antisense oligodeoxynucleotides directed against Kv1.5 mRNA specifically inhibit ultrarapid delayed rectifier K+ current in cultured adult human atrial myocytes. , 1997, Circulation research.

[22]  S Nattel,et al.  Sustained depolarization-induced outward current in human atrial myocytes. Evidence for a novel delayed rectifier K+ current similar to Kv1.5 cloned channel currents. , 1993, Circulation research.